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amenable to widespread use. Despite the considerable
chemical and methodological challenges remaining,
sorting out the distinctive functions of O-GlcNAcylated
or O-phosphorylated forms of regulatory molecules
will be key to understanding the regulation of signaling
and transcription and the assembly of the cytoskeleton,
as well as being important for developing treatments for
diabetes, neurodegenerative disorders, and cancer.
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Figure 1. Regulation of Estrogen Receptor b by Alternate O-GlcNA-
cylation or O-Phosphorylation at Ser16
O-GlcNAcylation by O-linked N-acetylglucosamine transferase (OGT)
at Ser16 enhances the b-turn conformation at the N terminus, leading
to decreased ER-b activity, but it also results in stabilization of the
protein, increasing its half-life within the cell. In contrast, O-phosphor-
ylation at Ser16 causes the N terminus to adopt a more extended
conformation, leading to increased transcriptional activity, but also
causing the protein to become rapidly degraded within the cell.
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924A Noncanonical Path
to Mechanism of Action
Improved methods for discovering small-molecule
mechanisms of action are needed. In this issue of
Chemistry & Biology, Zhang et al. [1] make clever use
of the zebrafish to study the mechanism of the angio-
genesis inhibitor fumagillin and reveal that it targets
the noncanonical Wnt pathway.
Few things are more intriguing in the world of chemical
biology than a small molecule with pronounced biologi-
cal activity and therapeutic importance for which little is
known of its mechanism of action. Deciphering these
molecules’ mechanisms of action can provide surprising
biological insights and avenues for novel therapeutic
approaches. One such small molecule is fumagillin, a
natural product serendipitously discovered to inhibit
endothelial cell proliferation. Fumagillin and its deriva-
tive TNP-470 are potent inhibitors of angiogenesis and
have been the focus of numerous basic and clinical
studies [2]. Although fumagillin has been shown to tar-
get methionine aminopeptidase 2 (MetAP-2) [3], little is
known about how MetAP-2 inhibition exerts its antian-
giogenic influence.In this issue of Chemistry & Biology, Zhang et al. [1]
employ a clever combination of in vivo and in vitro ex-
periments to uncover an unexpected connection be-
tween MetAP-2 and noncanonical Wnt signaling. Their
approach takes advantage of the zebrafish, a genetic
model organism for which thousands of mutations and
their phenotypes have been characterized and cata-
loged [4, 5]. Each mutant zebrafish embryo can be
thought of as providing a three-dimensional readout of
a gene’s biological activity. The rich variety of zebrafish
phenotypes makes it possible to characterize in detail
the effects of disrupting a single gene product and to
link a specific embryonic phenotype with the molecular
disruption that causes it. The authors reasoned that
treating zebrafish embryos with TNP-470 might also
produce a distinct phenotype, and that by comparing
the resultant phenotype with those cataloged for zebra-
fish gene mutations, they might be able to learn what
pathway is targeted by TNP-470 (Figure 1).
In many cases, zebrafish embryos can be treated with
small molecules simply by adding the molecules to the
water in which the embryos are developing [6]. When
the authors exposed developing zebrafish embryos to
fumagillin or TNP-470, the embryos developed a defect
in the anterior-posterior axis that resulted in a severely
truncated tail. They also observed the same develop-
mental defect in zebrafish embryos in which MetAP-2
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925Figure 1. Use of Zebrafish for Deciphering
Small-Molecule Mechanisms of Action
Treating zebrafish embryos with a small
molecule often generates a distinctive phe-
notype. By comparing the phenotype with
databases of existing zebrafish phenotypes,
candidate targets for the small molecule can
often be identified. As described in this issue,
fumagillin causes a truncated tail phenotype
similar to that caused by Wnt5 mutation and
other perturbations of noncanonical Wnt
signaling.expression was knocked down using antisense mor-
pholino oligonucleotides (morpholinos). By examining
descriptions of previously characterized zebrafish phe-
notypes, the authors recognized that the fumagillin/
MetAP-2 phenotype was similar to that of the Wnt5 mu-
tant pipetail and to embryos injected with Wnt5 morpho-
linos [7]. These observations suggested an unexpected
link between MetAP-2 and Wnt5. The idea of a MetAP-2/
Wnt5 connection was reinforced when the authors in-
jected zebrafish with lower doses of morpholinos target-
ing MetAP-2 and Wnt5. Doses that produced only mild
tail phenotypes individually produced a severe tail trun-
cation phenotype when combined, suggesting an inter-
action between MetAP-2 and Wnt5.
The fact that fumagillin-treated zebrafish phenocopy
Wnt5 mutants suggests that fumagillin may exert its bi-
ological effects through inhibition of Wnt signaling. The
Wnt proteins are a large family of diffusible extracellular
ligands that perform central functions during numerous
developmental and disease processes [8]. The various
Wnt proteins share some common downstream effec-
tors, but two rather different classes of signal can be
transduced. The canonical Wnts signal through the
receptor Frizzled1, resulting in the stabilization of
b-catenin, which translocates to the nucleus and pro-
motes T cell factor (TCF)-dependent transcription [8].
Noncanonical Wnt signaling, by contrast, is mediated
through the receptor Frizzled2 and results in intracellular
calcium release and actin cytoskeleton rearrangement
(see Zhang et al. [1], Figure 1).
After their zebrafish experiments suggested Wnt sig-
naling in the fumagillin mechanism of action, the authors
turned to cultured cells to distinguish between effects
on canonical and noncanonical signaling. A mouse te-
ratocarcinoma system was used that enables specific
activation of canonical or noncanonical Wnt signaling.
Activation of either pathway leads to differentiation of
the cells into primitive endoderm. Crews and colleagues
showed that TNP-470 treatment or siRNA-mediated
knockdown of MetAP-2 could block primitive endoderm
differentiation mediated through noncanonical Wnt sig-
naling, but not through canonical Wnt signaling. This
remarkable result suggests that TNP-470 blocks nonca-
nonical Wnt signaling without affecting the canonical
pathway, making it the first small molecule known to
specifically target this pathway.
Zhang et al. went on to localize TNP-470’s point of
action further, placing it downstream of Frizzled2 and
upstream of the noncanonical Wnt effectors CamKII,
c-Jun, and RhoA. They stopped short, however, of iden-tifying a relevant enzymatic substrate for MetAP-2 itself,
a point that will undoubtedly receive significant future
attention. Additional effort is also needed to solidify
the importance of noncanonical Wnt signaling in mediat-
ing TNP-470’s antiangiogenic effects. The authors take
a step in that direction by demonstrating that an activated
form of the Wnt effector Disheveled-2 can partially rescue
endothelial cells from the cytostatic effect of TNP-470.
The identification of fumagillin/TNP-470 as specific in-
hibitors of noncanonical Wnt signaling will likely be of
great interest to those studying the Wnt pathway. Sub-
stantial overlap between the canonical and noncanoni-
cal pathways has made it difficult, in many instances,
to distinguish between canonical and noncanonical sig-
nals [8]. A small molecule capable of specific inhibition
of noncanonical signaling may be helpful in this
regard. In addition, the Wnt pathway is required for mul-
tiple processes at numerous stages of development. A
small molecule capable of inactivating the pathway con-
ditionally (e.g., with temporal control) should facilitate
study of later processes without the complications of
disrupting earlier Wnt signals.
Beyond fundamental research, the discovery of a link
between noncanonical Wnt signaling and angiogenesis
may have therapeutic implications. If inhibition of nonca-
nonical Wnt signaling blocks angiogenesis, then compo-
nents of the noncanonical Wnt pathway might be viewed
as potential new targets for antiangiogenesis. Given that
pathway inhibition causes a distinctive tail truncation
phenotype in zebrafish, it is easy to envision roles for the
zebrafish in discovery of novel noncanonical Wnt inhibi-
tors. For example, large-scale small-molecule screens
are feasible in the zebrafish [6], and one could screen
for small molecules that induce a tail truncation pheno-
type like that seen with fumagillin treatment, MetAP-2
knockdown, and Wnt5 mutation. Alternatively, tradi-
tional angiogenesis assays could be used to identify ac-
tive small molecules, with the zebrafish used to identify
those that function via the noncanonical Wnt pathway.
Could the combination of zebrafish phenotyping and
cellular assays employed so effectively by Crews and
coworkers become a standard approach for decipher-
ing small-molecule mechanisms of action? The authors
of this report clearly benefited from the fact that MetAP-
2 inhibition causes a distinctive phenotype that was
represented in existing zebrafish databases. It is unlikely
that every small molecule would cause such a distinctive
phenotype, or that every phenotype could be so readily
associated with a specific biological pathway. Neverthe-
less, the report by Zhang et al. clearly demonstrates the
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926power of the high-resolution phenotyping afforded by
zebrafish and the value of the large-scale databases
linking phenotype and genotype in this organism. As
these databases progress toward completeness, the
validity of the approach will continue to increase. Al-
though this strategy is unlikely to be universally effec-
tive, the fumagillin success makes a strong case for
considering the approach as a potent, albeit ‘‘nonca-
nonical,’’ path to deciphering small-molecule mecha-
nisms of action.
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A Stability Switch for Proteins
A paper published in the September 8 issue of Cell [1]
describes a generally applicable approach for chemi-
cal control of protein stability, with potential for broad
use in chemical genetics.
An oft-stated goal for chemical biology is to provide new
tools for analyzing gene and protein function that com-
plement classical genetics. This aspiration, encapsu-
lated in the phrase ‘‘chemical genetics,’’ is increasingly
being fulfilled as chemical probes are used to inhibit pro-
teins of interest and generate chemically-induced alleles
of protein function [2].
What chemistry has to offer genetics above all else is
the dimension of time [2, 3]. Essentially, small molecules
can be used to effect ‘‘instant mutagenesis’’ by specifi-
cally inhibiting (or activating) a protein of interest in real
time. By contrast, generation of knockout mice to look at
the functional consequences of protein loss is a slow
process, often stymied by embryonic lethality or con-
founding compensatory changes in gene expression.
RNAi [4] provides a new way to knock down protein
function, but is still slower to take effect as it does not di-
rectly target the protein. Thus, chemical approaches
have the potential to illuminate otherwise invisible areas
of biology.
Unfortunately, as a field we are not yet at a point where
we can routinely generate suitable chemical inhibitors
for every protein of interest. This is particularly true if
in vivo studies are contemplated, meaning that the addi-
tional hurdle of pharmacology needs to be cleared. An
alternative strategy is to ‘‘tag’’ a protein of interest in such
a way that it can be targeted by a generic ligand—forSelected Reading
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example by fusing it to a heterologous protein [3]. This
powerful approach in principle allows any protein of in-
terest to be chemically manipulated in real time without
the need for a specific inhibitor. ‘‘Tagging’’ strategies
have both drawbacks and advantages. They assume
that protein function is unaffected by the tag, and they
also require genetic steps to express the modified pro-
tein in cells. In addition, because endogenous, unmodi-
fied protein molecules will be unaffected by the generic
ligand, either the protein of interest needs to have a dom-
inant effect, or the study needs to be performed in the
background of a knockout of the endogenous protein.
On the other hand, since the effects of the small molecule
are restricted to cells expressing the tagged protein,
these approaches can often be more precise than the
use of a direct chemical inhibitor.
Many successful ‘‘tagging’’ strategies have been de-
scribed [3]. For example, dimeric small molecules can
be used to inducibly dimerize tagged proteins, allowing
study of proteins and pathways controlled by protein-
protein associations [5, 6]. Expression of protein kinases
that are modified to bind certain inhibitors uniquely has
allowed very precise delineation of the roles of individual
kinases and substrates in cell biology [7]. Several of
these technologies have ‘‘crossed over’’ from the field
of chemical biology to become established mainstream
biological research tools. However, they are generally
restricted to subsets of proteins that share a certain
mechanism of action. A truly versatile technology for
chemically regulating protein function, generally appli-
cable to any protein, is a highly desirable goal.
Such an approach was described a few years ago by
Stankunas et al. [8], who developed a system for con-
trolling protein stability—a shared property essential to
all proteins (see Figure 1). These authors exploited the
chance observation that a certain mutated protein
